🇺🇸 FDA
Pipeline program

JZP3507

JZP3507-202

Phase 2 small_molecule active

Quick answer

JZP3507 for Meningioma is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Meningioma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials